Cancer medicine · 2025
Maritoclax Overcomes FBW7 Deficiency-Driven Irinotecan Resistance in Colorectal Cancer by Targeting MCL1.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lin Qian, Liu Shuting, Jiang Hongfei, Wang Shasha, Duan Yixin
Аннотация
INTRODUCTION: FBW7, a tumor suppressive E3 ubiquitin ligase frequently mutated in colorectal cancer (CRC), mediates chemotherapy resistance. While irinotecan (via its active metabolite SN38) is a first-line TOP1 inhibitor for advanced CRC, the mechanistic link between FBW7 dysfunction and irinotecan resistance remains elusive.
METHODS: CRISPR/Cas9 gene editing and RNA interference were applied to establish FBW7-knockout and -knockdown CRC cells. CCK8 assay was performed to detect the inhibition ratio of SN38 and Maritoclax on CRC cells. Western blot, immunochemistry, RT-qPCR and co-immunoprecipitation were performed to detect the expression and interaction of FBW7 and MCL1. The conformational change of the FBW7 R465C mutation and its interaction with substrates were elucidated through AlphaFold. An animal experiment was performed to detect the in vivo therapeutic effect of irinotecan and Maritoclax.
RESULTS: FBW7 deficiency (including loss, low expression and mutation) reduced SN38 sensitivity and upregulated MCL1 expression in both CRC cells and patient tissues. The R465C mutation disrupted FBW7-MCL1 binding and stabilized MCL1. Moreover, SN38 modulated MCL1 expression, elevated MCL1 expression led to SN38 resistance in CRC cells. Maritoclax, a specific MCL1 inhibitor, reversed irinotecan/SN38 resistance in FBW7-deficient CRC cells and xenograft models, synergizing with irinotecan to suppress tumor growth.
CONCLUSIONS: FBW7 deficiency induces irinotecan resistance via MCL1 stabilization, which is therapeutically exploitable by Maritoclax. Our work identifies MCL1 inhibition as a precision strategy for FBW7-deficient CRC and supports clinical translation of Maritoclax-irinotecan combinations.
METHODS: CRISPR/Cas9 gene editing and RNA interference were applied to establish FBW7-knockout and -knockdown CRC cells. CCK8 assay was performed to detect the inhibition ratio of SN38 and Maritoclax on CRC cells. Western blot, immunochemistry, RT-qPCR and co-immunoprecipitation were performed to detect the expression and interaction of FBW7 and MCL1. The conformational change of the FBW7 R465C mutation and its interaction with substrates were elucidated through AlphaFold. An animal experiment was performed to detect the in vivo therapeutic effect of irinotecan and Maritoclax.
RESULTS: FBW7 deficiency (including loss, low expression and mutation) reduced SN38 sensitivity and upregulated MCL1 expression in both CRC cells and patient tissues. The R465C mutation disrupted FBW7-MCL1 binding and stabilized MCL1. Moreover, SN38 modulated MCL1 expression, elevated MCL1 expression led to SN38 resistance in CRC cells. Maritoclax, a specific MCL1 inhibitor, reversed irinotecan/SN38 resistance in FBW7-deficient CRC cells and xenograft models, synergizing with irinotecan to suppress tumor growth.
CONCLUSIONS: FBW7 deficiency induces irinotecan resistance via MCL1 stabilization, which is therapeutically exploitable by Maritoclax. Our work identifies MCL1 inhibition as a precision strategy for FBW7-deficient CRC and supports clinical translation of Maritoclax-irinotecan combinations.